



The role of migrating leukocytes in IL-1 β -induced up-regulation of kinin B₁ receptors in rats

¹Maria M. Campos, ²Glória E.P. de Souza, ³Natasha D. Ricci, ³Jorge L. Pesquero, ⁴Mauro M. Teixeira & *¹João B. Calixto

¹Department of Pharmacology, Center of Biological Sciences, Universidade Federal de Santa Catarina, 88015-420 - Florianópolis, SC, Brazil; ²Laboratory of Pharmacology, Faculty of Pharmacy, Universidade de São Paulo, Ribeirão Preto, Brazil; ³Department of Physiology and Biophysics, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil and ⁴Department of Biochemistry and Immunology, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil

1 The present study examines the role of migrating leukocytes in the ability of IL-1 β to induce the functional up-regulation of B₁ receptors, as assessed by kinin B₁ agonist-induced oedema in the rat paw.

2 Pre-treatment with the PAF receptor antagonist WEB 2086 inhibited des-Arg⁹-BK-induced oedema in IL-1 β -treated paws, while the LTB₄ receptor antagonist CP105696 had no effect. Des-Arg⁹-BK-induced paw oedema was also inhibited by pre-treatment with the selectin blocker fucoidin or by an anti-CD-18 monoclonal antibody.

3 I.d. injection of IL-1 β produced a 5–10-fold increase of myeloperoxidase (MPO) activity in the rat paw. The increase in MPO activity was significantly inhibited by WEB 2086 (46 \pm 9%), fucoidin (68 \pm 5%) or the CD-18 antibody (84 \pm 3%). In contrast, i.d. injection of TNF α a dose known to upregulate the B₁ receptor functionally did not induce any significant increase in MPO activity.

4 Des-Arg⁹-BK alone had no effect in MPO activity but enhanced (by about 40%) the response induced by IL-1 β , an effect prevented by the B₁ receptor antagonist des-Arg⁹-[Leu⁸]-BK.

5 The concentration of TNF- α was increased in the paws after i.d. injection of IL-1 β . Pre-treatment with fucoidin, WEB 2086, anti-CD-18 or CP 105695, significantly reversed the local increases in TNF- α concentrations (80 \pm 2; 75 \pm 4, 73 \pm 3 and 40 \pm 2%), respectively.

6 Finally, IL-1 β induced an increase of B₁ receptor mRNA levels in the rat paw, an effect which was prevented by fucoidin treatment.

7 Taken together, these results indicate that up-regulation of B₁ receptors in the rat paw following IL-1 β seems to involve the local recruitment of neutrophils and subsequent local TNF- α production. The cross-talk between kinins, cytokines and leukocytes implicate B₁ receptors in chronic inflammatory diseases.

British Journal of Pharmacology (2002) **135**, 1107–1114

Keywords: Kinins; B₁ receptor expression; rat paw oedema; inflammation; neutrophils; cytokines; adhesion molecules

Abbreviations: BK, bradykinin; BSA, bovine serum albumine; des-Arg⁹-BK, des-Arg⁹-bradykinin; i.d., intradermal; IL, interleukin; LTB₄, leukotriene B₄; MAP-kinase, mitogen-activated protein kinase; MPO, myeloperoxidase; NF- κ B, nuclear factor κ B; PAF, platelet activating factor; PBS, phosphate buffered saline, PMSF, phenylmethylsulphonyl fluoride; TNF- α , tumour necrosis factor- α

Introduction

Interleukin-1 (IL-1) α and β and related pro-inflammatory cytokines have been depicted as pleiotropic regulators of inflammatory and immune responses, affecting many distinct peripheral and central nervous system functions. The most relevant biological effects of IL-1 include the stimulation of lymphocytes, the activation of leucocytes at the site of inflammation, induction of fever, besides the increase of the production of prostaglandins, nitric oxide and chemokines (Dinarello, 2000a, b). IL-1 downstream pathways are linked to the activation of a wide range of intracellular signalling cascades, such as MAP-kinases and stimulation of transcrip-

tional factors (Saklatvala *et al.*, 1999; Bowie & O'Neill, 2000). Therefore, IL-1 has a complex biological role, and its actions are often related to the synthesis of new inflammatory proteins and seems to be dependent on the expression of several inflammatory components (Barnes & Adcock, 1997; Barnes & Karin, 1997).

The kinin system represents one of the inflammatory pathways known to be regulated by cytokines, especially IL-1 β . The actions of kinins are mediated by the activation of two seven transmembrane G protein-coupled receptors, namely B₁ and B₂ receptors (Marceau & Bachvarov, 1998; Calixto *et al.*, 2000). Whereas B₂ receptors are constitutive and responsible for the most relevant physiological actions of kinins, B₁ receptors are described as atypical, since they are not normally expressed in physiological conditions, but their expression is increased after tissue injury, during chronic inflammatory

*Author for correspondence at: Department of Pharmacology, Universidade Federal de Santa Catarina, Rua Ferreira Lima, 82, 88015-420, Florianópolis, SC, Brazil;
E-mail: calixto@farmaco.ufsc.br or calixto3@terra.com.br

processes and by the action of certain pro-inflammatory cytokines (for review see: Marceau *et al.*, 1998; Calixto *et al.*, 2000). In fact, recent studies have reported that IL-1 β , either *in vitro* or *in vivo*, acts as one of the most important modulators of B₁ receptor up-regulation (Marceau *et al.*, 1998; Calixto *et al.*, 2000). It has also been demonstrated that up-regulation of B₁ receptors by IL-1 β requires the stimulation of certain protein kinases, such as protein kinase C, tyrosine kinase and MAP kinases, as well as the activation of the nuclear transcription factor NF- κ B (Larrivée *et al.*, 1998; Marceau *et al.*, 1998; Schanstra *et al.*, 1998; Campos *et al.*, 1999). However, recent evidence has suggested that, in spite of the involvement of several signalling mechanisms, the induction of B₁ receptors by IL-1 β constitutes a very rapid process (Campos *et al.*, 1999; Phagoo *et al.*, 2000).

One of the most important characteristics of IL-1 β actions is its well-known ability to induce neutrophil migration and adhesion to the endothelium (Thorlacius *et al.*, 1997; Derevianko *et al.*, 1998; Grutkoski *et al.*, 1999). Despite this evidence, to the best of our knowledge, so far there has been no studies indicating a direct relationship between IL-1 β -induced local cell migration and the process of B₁ kinin receptors up-regulation in rats. Thus, in the present study we have assessed the role exerted by leukocyte migration in the process of B₁ kinin receptors up-regulation in the rat paw, in animals previously treated with IL-1 β .

Methods

Measurement of rat paw oedema

Non-fasted male Wistar rats (140–180 g) kept in controlled room temperature (22 \pm 2°C) under a 12:12 h light-dark cycle (lights on 06:00 h) were used. The experiments were conducted according to the procedures described previously (Campos & Calixto, 1995). The animals received a 0.1 ml intradermal (i.d.) injection in one hindpaw (right paw) of phosphate buffered saline (PBS, composition mmol L⁻¹): NaCl 137, KCl 2.7 and phosphate buffer 10, containing des-Arg⁹-BK (100 nmol paw⁻¹). The contralateral paw (left paw) received 0.1 ml of PBS and was used as control. Oedema was measured by use of a plethysmometer (Ugo Basile) at several time-points (10, 20, 30, 60 and 120 min) after injection of des-Arg⁹-BK. Oedema is expressed in ml as the difference between the right and left paws. In most cases, animals were treated with the cytokine IL-1 β (5 ng paw⁻¹; 60 min prior) at the same site as des-Arg⁹-BK injection, as described beforehand (Campos *et al.*, 1998). In all experiments, the i.d. injections were performed under slight anaesthesia with 2,2,2 tribromoethanol (0.125 g kg⁻¹). The reported experiments were carried out in accordance with current guidelines for the care of laboratory animals and ethical guidelines for investigations of experiments in conscious animals (Zimmerman, 1983).

Involvement of cell migration on des-Arg⁹-BK-induced oedema in IL-1 β pre-treated animals

In separate groups of animals, in order to determine the possible involvement of neutrophil-active chemoattractants in B₁ kinin receptors up-regulation, rats were administered the PAF receptor antagonist WEB 2086 (15 μ g paw⁻¹) or the

LTB₄ receptor antagonist CP 105696 (30 μ g paw⁻¹) co-injected with the cytokine IL-1 β (5 ng paw⁻¹), 60 min before des-Arg⁹-BK (100 nmol paw⁻¹) injection. In other sets of experiments, in order to examine the participation of adhesion molecules in IL-1 β -mediated B₁ kinin receptors up-regulation, animals were treated with the non-specific selectin inhibitor fucoidin (10 mg kg⁻¹, i.v.) or with the monoclonal anti-CD18 (integrin β 2 chain) antibody (WT3, 1 mg kg⁻¹, i.v.), both administered 15 min before IL-1 β treatment. The oedema was induced by i.d. injection of des-Arg⁹-BK (100 nmol paw⁻¹) and assessed as described before. The doses of all inhibitors have been chosen on the basis of previous studies or through pilot experiments (Dimartino *et al.*, 1989; Williams *et al.*, 1994; Búrigo *et al.*, 1996; Teixeira & Hellewell, 1997).

Measurement of MPO activity

The accumulation of neutrophils in the rat paw was measured by means of tissue MPO activity. Animals received a 0.1 ml i.d. injection of IL-1 β (1 and 5 ng paw⁻¹), TNF α (5 ng paw⁻¹) or des-Arg⁹-BK (100 nmol paw⁻¹) in the right paw and were sacrificed after 60, 30 and 20 min, respectively. In some experiments, animals pretreated with IL-1 β (1 and 5 ng paw⁻¹, 60 min) received an i.d. injection of des-Arg⁹-BK (100 nmol paw⁻¹) in the presence or absence of the selective B₁ receptor antagonist des-Arg⁹-[Leu⁸]-BK (100 nmol paw⁻¹) and were sacrificed after a further 20 min. PBS-treated paws were used as controls. In other sets of experiments, the MPO activity was assessed in animals that received a co-injection of WEB 2086 (15 μ g paw⁻¹) or CP 105696 (30 μ g paw⁻¹) or in rats pretreated with fucoidin (10 mg kg⁻¹, i.v.) or with the anti-CD-18 antibody (1 mg kg⁻¹, i.v.), the latter two treatments administered 15 min prior to IL-1 β injection.

At the time of sacrifice, the subcutaneous tissue of the paws was removed and assayed for MPO according to a method previously described (Souza *et al.*, 2000b). Briefly, tissues were homogenized at 5% (w v⁻¹) in EDTA/NaCl buffer (pH 4.7) and centrifuged at 3000 \times g for 15 min, at 4°C. The pellet was re-suspended in hexadecyltrimethyl ammonium bromide 0.5% buffer (pH 5.4) and the samples were frozen and thawed for three times in liquid nitrogen. Upon thawing, the samples were re-centrifuged (3000 \times g, 15 min, at 4°C) and 25 μ l of the supernatant were used for the MPO assay. The enzymatic reaction was assessed with 1.6 mM tetramethylbenzidine, 80 mM NaPO₄ and 0.3 mM hydrogen peroxide. The absorbance was measured at 690 nm and the results are expressed in optical density (OD) per mg of dry tissue.

Expression of B₁ receptor mRNA in the rat paw

The methodology used was similar to that described by Bélichard *et al.* (2000) and Schaeffer *et al.* (2001) with some modifications. Rats received IL-1 β (5 ng paw⁻¹) and were sacrificed after various intervals of time (15–360 min). In another group of experiments, animals were systemically treated with the non-selective inhibitor of selectins fucoidin (10 mg kg⁻¹, i.v.), 15 min before IL-1 β injection (5 ng paw⁻¹, 60 min). Immediately after the sacrifice, the subcutaneous tissue of the paws was removed and frozen in liquid nitrogen. The samples were then homogenized and the total RNA was extracted using the Trizol Reagent (Gibco BRL[®]). One μ g of total RNA were reverse transcribed (RT) using oligo dT as

primer (25 $\mu\text{g ml}^{-1}$) and 200 u of reverse transcriptase (Gibco BRL[®]), in 20 μl of PCR buffer containing (mM): dNTP 0.5, DTT 10, MgCl₂ 2.5, KCl 50 and Tris-HCl pH 8.4 20. The samples were incubated for 50 min at 42°C, heated for 15 min at -70° and cooled in ice. After treatment with 2 U of Rnase H (20 min, 37°C), cDNA amplification of a specific sequence of rat B₁ receptor and β -actin was performed by PCR using the following primers: sense TGAAGCTGTGAGCTCTTTG and antisense GCCAGTTGAAACGGTTCCTCC for B₁ receptor and sense GTTCCGATGCCCCGAGGATCT and antisense GCATTTGCGGTGCACGATGGA for rat β -actin. β -actin cDNA was used for standardization of the amount of RNA. 5 μl of RT aliquots were mixed in a 20 mM Tris-HCl buffer (pH 8.4) containing: 1.5 mM MgCl₂, 300 μM dNTP, 2 $\mu\text{g ml}^{-1}$ of each primer and 50 u ml⁻¹ of *Taq* polymerase (Gibco BRL[®]), in a final volume of 100 μl . The cycling protocol used was the following: 4 min at 94°C, 36 cycles of 35 s at 94°C/45 s at 60°C/45 s at 72°C and finally, 7 min at 72°C. Aliquots of 25 μl were analysed on a 20% TBE (Tris/Borate/EDTA) polyacrylamide gel and stained by ethidium bromide. The size of products are 423 bp for B₁ receptor and 361 bp for β -actin. The number of replicates was four.

Measurement of TNF α levels in the rat paw

TNF- α production in the rat paw was assessed using a sandwich ELISA, as previously described (Souza *et al.*, 2000a). Briefly, animals received an i.d. injection of IL-1 β (5 ng per paw) and after 60 min, rats were sacrificed and the subcutaneous tissue of the paws removed and placed in a PBS solution containing: Tween 20 0.05%, PMSF 0.1 mM, EDTA 10 mM, Aprotinin A 20 KI and BSA 0.5%. Tissues were homogenized, centrifuged at 3000 \times g, for 10 min and the supernatant obtained was stored at -70°C until further analysis. In order to evaluate a role for neutrophils in control of local TNF- α production, neutrophil migration into tissue was prevented by pre-treatment with WEB2086, fucoidin or the anti-CD18 monoclonal antibodies, used in the same doses as described above.

Drugs and reagents

The following drugs were used: aprotinin, BSA, des-Arg⁹-BK, fucoidin, 2,2,2 tribromoethanol, PBS tablets, EDTA, hexadecyltrimethyl ammonium, tetramethylbenzidine and PMSF (all from Sigma Chemical Company, St. Louis, MO, U.S.A.). WEB 2086 was a gift of Boehringer-Manhein, Germany, CP 105696 was from Pfizer Global Research and Development, Groton labs, CT, U.S.A. and the anti-CD 18 mAb from Dr Paul Hellewell, University of Sheffield, U.K. NaPO₄, NaCl, hydrogen peroxide and Tween 20 were all from Merck, Germany. Recombinant murine cytokine IL-1 β (Lot BN091) was obtained from R & D Systems INC., Minneapolis, U.S.A. The stock solutions of des-Arg⁹-BK and des-Arg⁹-[Leu⁸]-BK were prepared in PBS in siliconized plastic tubes maintained at 18°C and diluted to the desired concentration just before use. The other drugs were prepared daily in 0.9% w v⁻¹ NaCl solution.

Statistical analysis

The results are presented as the mean \pm s.e.mean of 4–6 animals. The percentages of inhibition are reported as

mean \pm s.e.mean of inhibitions obtained in each individual experiment at the peak of oedema (20 min after injection of des-Arg⁹-BK) or at 60 min after IL-1 β injection. Statistical comparison of the data was performed by analysis of variance (ANOVA) followed by Dunnett's test or Newman-Keuls test or by use of Student's unpaired *t*-test. *P* values less than 0.05 were considered significant.

Results

We have reported previously that the i.d. injection of IL-1 β was able to induce the up-regulation of kinin B₁ receptor-mediated oedematogenic responses (Campos *et al.*, 1998). Accordingly, the i.d. injection of the selective kinin B₁ receptor agonist des-Arg⁹-BK (100 nmol paw⁻¹) in naive paws induced a very slight increase in rat paw volume (0.08 \pm 0.003 ml, *n* = 4), whereas i.d. injection of des-Arg⁹-BK in animals pre-treated with IL-1 β (5 ng paw⁻¹, 60 min before) produced a marked increase in oedema (0.54 \pm 0.03 ml, *n* = 4). Histological assessment of sites injected with IL-1 β demonstrated that significant accumulation of leukocytes, specially neutrophils, could be seen and correlated with the kinetics of the functional up-regulation of the kinin B₁ receptor (Campos *et al.*, 1998 and data not shown).

In order to investigate the role of migrating leukocytes in the functional up-regulation of kinin B₁ receptors, animals were pretreated with drugs known to regulate leukocyte recruitment *in vivo*. As seen in Figure 1A, the oedema induced by des-Arg⁹-BK in animals pre-treated with IL-1 β was significantly inhibited by 37 \pm 5% by the co-injection of the PAF receptor antagonist WEB 2086 (15 $\mu\text{g paw}^{-1}$). In contrast, the co-injection of the LTB₄ receptor antagonist CP 105696 (30 $\mu\text{g paw}^{-1}$), at a dose that significantly inhibited the rat paw oedema caused by arachidonic acid (76 \pm 12% inhibition), failed to affect the oedema formation caused by des-Arg⁹-BK in IL-1 β -injected paws (Figure 1B). The treatment of animals with fucoidin (10 mg kg⁻¹, i.v., 15 min) resulted in a significant decrease (43 \pm 4%) of des-Arg⁹-BK-induced paw oedema in rats pre-treated with IL-1 β . Similarly, IL-1 β -mediated B₁ kinin receptor functional up-regulation was also significantly inhibited by the treatment of animals with an anti-CD18 mAb (WT3, 1 mg kg⁻¹, i.v., 15 min) (44 \pm 4%) (Figure 2A, B).

Intradermal injection of IL-1 β (1 and 5 ng paw⁻¹, 60 min) resulted in a marked neutrophil sequestration in the rat paw, as indicated by a 5–10-fold increase of MPO activity in IL-1 β -treated paws. Intradermal injection of the B₁ selective kinin receptor agonist des-Arg⁹-BK (100 nmol paw⁻¹, 20 min) did not induce any significant neutrophil recruitment when injected alone, but significantly enhanced (38 \pm 4%) the neutrophil influx induced by a low dose of IL-1 β (1 ng paw⁻¹, 60 min) (Figure 3A). The increase of MPO activity induced by des-Arg⁹-BK in rats pretreated with IL-1 β (1 ng paw⁻¹) was prevented by the co-injection of the B₁ receptor antagonist des-Arg⁹-[Leu⁸]-BK (100 nmol paw⁻¹) (33 \pm 6%) (Figure 3B). On the other hand, des-Arg⁹-BK injection failed to produce any additional increase in MPO activity, when assessed in rats previously treated with a higher dose (5 ng paw⁻¹, 60 min) of IL-1 β (results not shown).

The i.d. injection of TNF α (5 nmol paw⁻¹, 30 min) previously shown to induce the functional upregulation of




Figure 1 Effect of the treatment with the PAF receptor antagonist WEB 2086 (15 μ g paw⁻¹; (A) or with the LTB₄ receptor antagonist CP 105596 (30 μ g paw⁻¹; (B) on des-Arg⁹-BK (100 nmol paw⁻¹)-induced rat paw oedema in animals pretreated with IL-1 β (5 ng paw⁻¹, 60 min). Each point represents the means \pm s.e. mean of 4–6 experiments. In some cases the error bars are hidden within the symbols. Significantly different from control values **P* < 0.05 (Student's unpaired *t*-test).




Figure 2 Effect of treatment with the non-selective selectin inhibitor fucoidin (10 mg kg⁻¹, i.v., 15 min; (A) or with an anti-CD18 monoclonal antibody (1 mg kg⁻¹, i.v., 15 min; (B) on des-Arg⁹-BK (100 nmol paw⁻¹)-induced rat paw oedema in animals pretreated with IL-1 β (5 ng paw⁻¹, 60 min). Each point represents the means \pm s.e. mean of 4–6 experiments. In some cases the error bars are hidden within the symbols. Significantly different from control values **P* < 0.05 (Student's unpaired *t*-test).

B₁ receptor (Campos *et al.*, 1998) had no significant effects on the recruitment of neutrophils when compared with saline treated animals, as assessed by the MPO activity in the paws (0.0323 ± 0.0026 optic density per tissue mg in TNF α treated animals versus 0.0368 ± 0.0018 optic density per tissue mg in saline-treated rats, *n* = 3).

The effects of strategies which interfere with leukocyte migration on the functional up-regulation of kinin B₁ receptors induced by IL-1 β correlated with their ability to prevent the influx of neutrophils, as assessed by the tissue levels of MPO. As such, IL-1 β (5 ng paw⁻¹, 60 min)-induced increase in MPO activity was significantly prevented by the co-injection of the PAF receptor antagonist WEB 2086 (15 μ g paw⁻¹) ($46 \pm 9\%$), by the systemic treatment with fucoidin (10 mg kg⁻¹, i.v.) ($68 \pm 5\%$) or by the anti-CD18 antibody (1 mg kg⁻¹, i.v.) ($84 \pm 3\%$) (Figure 4).

Next, we investigated whether strategies which blocked neutrophil influx could also interfere with the IL-1 β -induced production of TNF- α concentrations. The injection of IL-1 β resulted in a marked increase of TNF α levels (Figure 5). Pretreatment with fucoidin, WEB 2086, the anti-CD18 antibody or CP-105695, significantly reversed the local increases in TNF- α concentrations (80 ± 2 ; 75 ± 4 , 73 ± 3 and $40 \pm 2\%$), respectively (Figure 5).

Finally, the results show that the time-dependent functional increase of B₁ receptors following IL-1 β injection (5 ng paw⁻¹, 15–360 min, number of replicates = 4) (Campos *et al.*, 1998) was accompanied by a marked increase in kinin B₁ receptor mRNA expression in the rat paw, as assessed by RT-PCR (Figure 6A). Furthermore, IL-1 β (5 ng paw⁻¹, 60 min)-induced increase in B₁ receptor mRNA was significantly inhibited by the systemic treatment with fucoidin ($49 \pm 5\%$) (Figure 6B).

Discussion

The crosstalk between cytokines and kinin receptors has been extensively investigated in the last years. Several lines of evidence have demonstrated that pro-inflammatory cytokines are able to regulate B₁ receptors expression through complex signalling mechanisms involving the activation of downstream kinases and transcription factors, especially NF- κ B (Larrivée *et al.*, 1998; Campos *et al.*, 1999; Phagoo *et al.*, 2000). In addition, the induction of B₁ kinin receptors by other stimuli, including lipopolysaccharide of *E. coli* or tissue trauma, likely involves the secondary production of cytokines, such as IL-1 β and TNF- α (Marceau, 1995; Marceau *et al.*, 1998). In this way, pro-inflammatory cytokines seem to exert a pivotal role

in the mechanisms mediating kinin responses, as they are capable of regulating B₁ kinin receptor expression during certain inflammatory conditions. Despite the experimental evidence demonstrating the possible mechanisms responsible for B₁ receptor up-regulation, the process is not entirely understood. The results of the present study demonstrated that IL-1 β -induced up-regulation of B₁ kinin receptor in the rat paw was largely dependent on the ability of the cytokine to induce local accumulation of neutrophils with consequent local TNF- α production. Neutrophil influx was PAF receptor- and cell adhesion molecule-dependent.

The release in tissue of chemoattractant molecules which act on seven-transmembrane G protein-associated receptors is an essential step for the recruitment of leukocytes (Mansson




Figure 3 (A) Effect of IL-1 β (1 and 5 ng paw⁻¹, 60 min) or des-Arg⁹-BK (100 nmol paw⁻¹, 20 min), given alone or after IL-1 β (1 ng paw⁻¹) i.d. injection, on MPO activity in the rat paw. (B) Effect of the co-injection of the B₁ receptor selective antagonist des-Arg⁹-[Leu⁸]-BK (100 nmol paw⁻¹) on IL-1 β (1 ng paw⁻¹, 60 min) plus des-Arg⁹-BK (100 nmol paw⁻¹, 20 min)-induced increase in MPO activity in the rat paw. Each column represents the means \pm s.e. mean of four experiments. Significantly different from values obtained in PBS- (*), IL-1 β - (#) or IL-1 β plus des-Arg⁹-BK (+) injected paws, $P < 0.05$ (one-way ANOVA followed by Newman-Keuls test).




Figure 4 Effect of treatment with CP 105696 (30 μ g paw⁻¹), WEB 2086 (15 μ g paw⁻¹), fucoidin (10 mg kg⁻¹, i.v., 15 min) or with the β 2 integrin-CD18 antibody (1 mg kg⁻¹, i.v., 15 min) on IL-1 β (5 ng paw⁻¹, 60 min)-induced increase in MPO activity in the rat paw. Each column represents the means \pm s.e. mean of four experiments. Significantly different from values obtained in IL-1 β -injected paws (*) $P < 0.05$ (one-way ANOVA followed by Dunnett's test).

Figure 5 Effect of treatment with CP 105696 (30 μ g/paw), WEB 2086 (15 μ g paw⁻¹), fucoidin (10 mg kg⁻¹, i.v., 15 min) or with the β 2 integrin-CD18 antibody (1 mg kg⁻¹, i.v., 15 min) on IL-1 β (5 ng paw⁻¹, 60 min)-induced increase in TNF α levels in the rat paw. Each column represents the means \pm s.e. mean of 4–5 experiments. Significantly different from values obtained in PBS- (*) or IL-1 β -injected paws (#) $P < 0.05$. (one-way ANOVA followed by Newman-Keuls test).




Figure 6 (A) Time-dependent effect of IL-1 β (5 ng paw⁻¹, 15–360 min) injection on kinin B₁ receptor expression in the rat paw. (B) Effect of systemic treatment with fucoidin (10 mg kg⁻¹, i.v., 15 min) on IL-1 β (5 ng paw⁻¹, 60 min)-induced increase in B₁ receptor expression. Bottom, graphic representation of B₁/ β -actin signals ratio. 1. PBS; 2. IL-1 β 15 min; 3. IL-1 β 30 min; 4. IL-1 β 60 min; 5. IL-1 β 120 min; 6. IL-1 β 360 min; 7. PBS; 8. IL-1 β 60 min; 9. Fucoidin 10 mg kg⁻¹, i.v. Number of replicates = 4.

et al., 2000; Rossi & Zlotnik, 2000; von Andrian & Mackay, 2000). Thus, we reasoned that IL-1 β was also inducing the local release of chemoattractant molecules that would drive the local influx of neutrophils. Here, we assessed the role of two of these mediators, PAF and LTB₄, known to be potent and effective inducers of neutrophil recruitment and activation (Liu *et al.*, 1996; Crooks & Stockley, 1998). In addition, PAF and LTB₄ can be induced by IL-1 β in different conditions (Nourshargh *et al.*, 1995; Showell *et al.*, 1998; Wen *et al.*, 1998; Serou *et al.*, 1999; Wang & Sun, 2000) and there are good pharmacological antagonists to evaluate their role *in vivo*. The data of the present study show that B₁ kinin receptors-mediated oedema in rats pretreated with IL-1 β was significantly inhibited by the co-injection of a selective PAF receptor antagonist. It has been reported that IL-1 β mediated leukocyte extravasation in mesenteric microvessels involves the formation of PAF (Nourshargh *et al.*, 1995). In addition, the pre-treatment with PAF receptor antagonists prevents IL-1 β -mediated cyclooxygenase-2 induction in primary hippocampal neuronal culture cells (Serou *et al.*, 1999). In contrast to the effects of the PAF receptor antagonist, the LTB₄ receptor antagonist had no significant effect on des-Arg⁹-BK-induced paw oedema in IL-1 β -treated rats. Together, the data above suggest that neutrophil recruitment in response to IL-1 β administration in the rat paw might be in part mediated by the endogenous release of PAF.

Our data also suggest that B₁ receptors up-regulation after i.d. injection of IL-1 β involves a process dependent on the activation of adhesion molecules. This conclusion derives from the observation that des-Arg⁹-BK-induced paw oedema was significantly inhibited by a non-selective selectin inhibitor, fucoidin, or by an anti-CD18 antibody. These results are in agreement with the ability of IL-1 β to induce the expression of adhesion molecules in the endothelium and, hence, to induce the influx of leukocytes to sites of inflammation (Meager, 1999; Mansson *et al.*, 2000). Indeed,

IL-1 β and other pro-inflammatory cytokines are capable of triggering the activation of protein kinase cascades and NF- κ B which, in turn, promote the expression of adhesion molecules, including selectins and integrins (Barnes & Karin, 1997; Stylianou & Saklatvala, 1998).

The injection of IL-1 β in the rat paw induced a significant influx of neutrophils, as assessed by a 5–10-fold increase in MPO activity. MPO is stored in cytoplasmic granules of neutrophils and represents an indirect, but relevant measurement of neutrophil sequestration. Blockade of PAF-receptors with WEB 2086 or of selectin- and CD18-dependent interactions with fucoidin and anti-CD mAb, respectively, markedly reduced the local neutrophil influx. As discussed above, these same inhibitors blocked not only IL-1 β -induced increase in MPO activity, but also reduced in a significant manner the functional up-regulation of B₁ receptors in rats pre-treated with IL-1 β . Overall, these results argue that the recruitment of neutrophils in response to IL-1 β administration is an essential prerequisite for the expression of a functional B₁ receptor. Our results evaluating the expression of B₁ receptor mRNA expression in the rat paw reinforce the latter concept. Indeed, the present work demonstrates for the first time a rapid up-regulation of B₁ receptor mRNA after injection of IL-1 β . Interestingly, this increase of B₁ mRNA expression following IL-1 β pre-treatment correlated well with the functional up-regulation of the receptor (Campos *et al.*, 1998; 1999). Furthermore, the ability of fucoidin to inhibit B₁ receptor mRNA reinforces the dependence of B₁ receptor induction on neutrophil recruitment.

We have previously shown that pre-treatment of animals with anti-TNF- α abrogates the ability of IL-1 β to upregulate the kinin B₁ receptor (Campos *et al.*, 1999). Moreover, we have also demonstrated that local TNF- α production was dependent on the influx of neutrophils following ischaemia and reperfusion injury of the superior mesenteric artery in rats (Souza *et al.*, 2000a). It was of interest then to investigate

whether IL-1 β -induced neutrophil influx could drive the local production of TNF- α , explaining the ability of neutrophils to induce the functional up-regulation of kinin B₁ receptors. This was particularly relevant as TNF- α did not induce significant neutrophil recruitment, as assessed by the local increase in MPO activity, at doses known to induce the functional upregulation of B₁ receptors (Campos *et al.*, 1998). Here, we show that the injection of IL-1 β into the rat paw induced a significant local production of TNF- α immunoreactivity. More importantly and in agreement with our previous studies in another model of acute neutrophil-dependent inflammation (Souza *et al.*, 2000a), blockade of neutrophil influx with fucoidin, the anti-CD18 mAb or the PAF receptor antagonist effectively blocked local TNF- α production. Unexpectedly, the LTB₄ receptor antagonist partially inhibited the local production of TNF- α without interfering with neutrophil recruitment or B₁ receptor functional upregulation. We do not have an explanation for these partial inhibitory effects of the LTB₄ receptor antagonist. One distinct possibility which arises from our previous work (Souza *et al.*, 2000b) is that LTB₄ receptors may be necessary for neutrophil activation and, thus, partially responsible for the local production of TNF- α , but not to an extent that would not interfere with B₁ receptor functional upregulation.

It is not clear from our studies how infiltrating neutrophils drive the local production of TNF- α . Nevertheless, the distinct ability of neutrophils to produce different oxygen species and inflammatory mediators and to interact with other cell types may underlie the observation above. For example, in some conditions, such as after i.d. IL-1 β injection, neutrophil-derived oxidants can act as second messengers in IL-1 β signalling pathways (Derevianko *et al.*, 1998). Whatever the underlying explanation, the present finding may bear relevance to many inflammatory conditions where infiltrating neutrophils are a major pathological feature. Thus, the results presented above demonstrate that the influx of neutrophils is necessary for the local production of TNF- α which may in turn drive the functional up-regulation of kinin B₁ receptors.

In addition to inducing local TNF- α release, neutrophils have been shown to express kinin B₁ receptors (Araújo *et al.*, 2001) and could, thus, be a direct target of the B₁ receptor agonist-induced paw oedema. Nevertheless, the i.d. injection of the selective kinin B₁ receptor agonist des-Arg⁹-BK did not induce any alteration in MPO activity when injected alone in the rat paw. In fact, when compared with other chemotactic factors, kinins, including BK, are described as weak inducers of cell migration. So, it has been suggested that the involvement of

kinins during cell recruitment, might be dependent on the interaction with other mediators of inflammation (Böckmann & Paegelow, 2000). Here, we show that des-Arg⁹-BK was able to induce a further increase of MPO activity (about 40%) in rats pre-treated with a low dose of IL-1 β (1 ng paw⁻¹). These results are in accordance with previous observations (Ahluwalia & Perretti, 1996; McLean *et al.*, 2000) which demonstrate the ability of des-Arg⁹-BK in stimulating neutrophil influx after IL-1 β priming. In addition, our results also suggest the involvement of B₁ receptors in des-Arg⁹-BK-induced responses, as the increase in MPO activity was significantly prevented by the co-injection of the B₁ receptor antagonist des-Arg⁹-[Leu⁸]-BK. Thus, cytokines and kinins may participate cooperatively in the fine regulation of neutrophil migration during the inflammatory process. As such, IL-1 β -induced neutrophil migration results in the TNF- α -dependent up-regulation of B₁ receptors, that in turn might amplify the cell influx in order to perpetuate the inflammatory response.

Interestingly and in contrast to the fundamental role of neutrophils shown here, it has been previously reported that depletion of circulating neutrophils had no effect on B₁ receptor-induced fall in blood pressure in LPS-treated rabbits (Bouthillier *et al.*, 1987). The reasons for the discrepancy is not known but there are several reasons which could account for the different need of neutrophils for local versus systemic B₁ receptor expression. For example, the cell types responding to the inflammatory stimuli and releasing B₁ receptor-inducing pro-inflammatory cytokines (such as TNF- α) could be different in the two different experiments. In this regard, we have previously demonstrated that strategies which block neutrophil influx were capable of abrogating the local, but not systemic, production of TNF- α following mesenteric ischemia and reperfusion injury in rats (Souza *et al.*, 2000a).

In conclusion, the results of the present study demonstrate that the injection of IL-1 β induces neutrophil recruitment into the paw *via* a mechanism that involves the participation of PAF receptors and adhesion molecules. The recruited neutrophils induce the local production of TNF- α which appears to drive the local up-regulation of B₁ receptors. The important cross-talk between the kinin system and cytokines suggest that studies evaluating the blockade of kinin receptors, specially the B₁ receptor, may be warranted in chronic inflammatory diseases where pro-inflammatory cytokines are expressed in great levels.

This work was supported by grants from CNPq, FINEP, PRONEX and FAPESP (Brazil). M.M. Campos is a PhD student receiving a grant from CNPq

References

- AHLUWALIA, A. & PERRETTI, M. (1996). Involvement of bradykinin B₁ receptors in the polymorphonuclear leucocyte accumulation induced by IL-1 β *in vivo* in the mouse. *J. Immunol.*, **156**, 269–274.
- ARAÚJO, R.C., KETTRITZ, R., FICHTNER, I., PAIVA, A.C.M., PESQUERO, J.B. & BADER, M. (2001). Altered neutrophil homeostasis in kinin B₁ receptor-deficient mice. *Biol. Chem.*, **382**, 91–95.
- BARNES, P.J. & ADCOCK, I.M. (1997). NF- κ B: a pivotal role in asthma and a new target for therapy. *Trends Pharmacol. Sci.*, **18**, 47–50.
- BARNES, P.J. & KARIN, M. (1997). Nuclear factor- κ B - a pivotal transcription factor in chronic inflammatory diseases. *N. Eng. J. Med.*, **336**, 1066–1071.
- BÉLICHARD, P., LANDRY, M., FAYE, P., BACHVAROV, D.R., BOUTHILLIER, J., PRUNEAUS, D. & MARCEAU, F. (2000). Inflammatory hyperalgesia induced by zymosan in the plantar tissue of the rat: effect of kinin receptor antagonists. *Immunopharmacology*, **46**, 139–147.
- BÖCKMANN, S. & PAEGELOW, I. (2000). Kinins and kinin receptors: importance for the activation of leukocytes. *J. Leukoc. Biol.*, **68**, 587–592.
- BOUTHILLIER, J., DEBLOIS, D. & MARCEAU, F. (1987). Studies on the induction of pharmacological responses to des-Arg⁹-bradykinin *in vitro* and *in vivo*. *Br. J. Pharmacol.*, **92**, 257–264.

- BOWIE, A. & O'NEILL, L.A. (2000). The interleukin-1 receptor/Toll-like receptor superfamily: signal generators for pro-inflammatory interleukins and microbial products. *J. Leukoc. Biol.*, **67**, 508–514.
- BÚRIGO, A.C., CALIXTO, J.B. & MEDEIROS, Y.S. (1996). Pharmacological profile of rat pleurisy induced by Bothrops jararaca venom. *J. Pharm. Pharmacol.*, **48**, 106–111.
- CALIXTO, J.B., CABRINI, D.A., FERREIRA, J. & CAMPOS, M.M. (2000). Kinins in pain and inflammation. *Pain*, **87**, 1–5.
- CAMPOS, M.M. & CALIXTO, J.B. (1995). Involvement of B₁ and B₂ receptors in bradykinin-induced rat paw oedema. *Br. J. Pharmacol.*, **114**, 1005–1013.
- CAMPOS, M.M., SOUZA, G.E.P. & CALIXTO, J.B. (1998). Modulation of kinin B₁ receptor-mediated rat paw oedema by IL-1 β and TNF α . *Peptides*, **19**, 1269–1276.
- CAMPOS, M.M., SOUZA, G.E.P. & CALIXTO, J.B. (1999). In vivo B₁ kinin-receptor up-regulation. Evidence for involvement of protein kinases and nuclear factor kappaB pathways. *Br. J. Pharmacol.*, **127**, 1851–1859.
- CROOKS, S.W. & STOCKLEY, R.A. (1998). Leukotriene B₄. *Int. J. Biochem. Cell. Biol.*, **30**, 173–178.
- DEREVIANKO, A., GRAEBER, T., D'AMICO, R. & SIMMS, H.H. (1998). The role of neutrophil-derived oxidants as second messengers in interleukin-1 β -stimulated cells. *Shock*, **10**, 54–61.
- DIMARTINO, M.J., WOLFF, C.E., CAMPBELL, G.K. & HANNA, N. (1989). The pharmacology of arachidonic acid-induced rat PMN leukocyte infiltration. *Agents and Actions*, **27**, 325.
- DINARELLO, C.A. (2000a). Proinflammatory cytokines. *Chest*, **118**, 503–508.
- DINARELLO, C.A. (2000b). The role of the interleukin-1 receptor antagonist in blocking inflammation mediated by interleukin-1. *N. Engl. J. Med.*, **343**, 732–734.
- GRUTKOSKI, P.S., D'AMICO, R., AYALA, A. & SIMMAS, H.H. (1999). IL-1 β stimulation induces paracrine regulation of PMN function and apoptosis. *Shock*, **12**, 373–381.
- LARRIVÉE, J.-F., BACHVAROV, D.R., HOULE, F., LANDRY, J., HUOT, J. & MARCEAU, F. (1998). Role of mitogen-activated protein kinases in the expression of the B₁ kinin receptors induced by tissue injury. *J. Immunol.*, **160**, 1419–1426.
- LIU, L., MUL, F.P., KUIJPERS, T.W., LUTTER, R., ROOS, D. & KNOL, E.F. (1996). Neutrophil transmigration across monolayers of endothelial cells and airway epithelial cells is regulated by different mechanisms. *Ann. NY Acad. Sci.*, **796**, 21–29.
- MANSSON, P., ZHANG, X.W., JEPSSON, B., JOHNELL, O. & THORLACIUS, H. (2000). Critical role of P-selectin-dependent rolling in tumor necrosis factor-induced leukocyte adhesion and extravascular recruitment *in vivo*. *Naunyn-Schmiedberg's Arch. Pharmacol.*, **362**, 190–196.
- MARCEAU, F. (1995). Kinin B₁ receptors: a review. *Immunopharmacology*, **30**, 1–26.
- MARCEAU, F. & BACHVAROV, D.R. (1998). Kinin receptors. *Clin. Rev. Allergy Inflamm.*, **16**, 385–401.
- MARCEAU, F., HESS, J.F. & BACHVAROV, D.R. (1998). The B₁ receptors for kinins. *Pharmacol. Rev.*, **50**, 357–386.
- MCLEAN, P.G., AHLUWALIA, A. & PERRETTI, M. (2000). Association between kinin B₁ receptor expression and leukocyte trafficking across mouse mesenteric postcapillary venules. *J. Exp. Med.*, **192**, 367–380.
- MEAGER, A. (1999). Cytokine regulation of cellular adhesion molecule expression in inflammation. *Cytokine Growth Factor Rev.*, **10**, 27–39.
- NOURSHARGH, S., LARKIN, S.W., DAS, A. & WILLIAMS, T.J. (1995). Interleukin-1-induced leukocyte extravasation across rat mesenteric microvessels is mediated by platelet-activating factor. *Blood*, **85**, 2553–2558.
- PHAGOO, S.B., YAQOUB, M., HERRERA-MARTINEZ, E., MCINTYRE, P., JONES, C. & BURGESS, G.M. (2000). Regulation of bradykinin receptor gene expression in human lung fibroblasts. *Eur. J. Pharmacol.*, **397**, 237–246.
- ROSSI, D. & ZLOTNIK, A. (2000). The biology of chemokines and their receptors. *Ann. Rev. Immunol.*, **18**, 217–243.
- SAKLATVALA, J., DEAN, J. & FINCH, A. (1999). Protein kinase cascades in intracellular signalling by interleukin-1 and tumor necrosis factor. *Biochem. Soc. Symp.*, **64**, 63–67.
- SCHAEFFER, P., LAPLACE, M.-C., SAVI, P., PRABONNAUD, V., SALEL, V., HERBERT, J.-M. (2001). Detection of bradykinin B₁ receptors in rat aortic smooth muscle cells. *Biochem. Pharmacol.*, **61**, 291–298.
- SCHANSTRA, J.P., BATAILLÉ, E., CASTAÑO, M.E.M., BARASCUD, Y., HIRTZ, C., PESQUERO, J.B., PECHER, C., GAUTHIER, F., GIROLAMI, J.-P. & BASCANDS, J.-L. (1998). The B₁-agonist [des-Arg¹⁰]-kallidin activates transcription factors NF- κ B and induces homologous up-regulation of the bradykinin B₁-receptor in cultured human lung fibroblasts. *J. Clin. Invest.*, **101**, 2080–2091.
- SEROU, M.J., DECOSTER, M.A. & BAZAN, N.G. (1999). Interleukin-1 β activates expression of cyclooxygenase-2 and inducible nitric oxide synthase in primary hippocampal neuronal culture: platelet activating factor as a preferential mediator of cyclooxygenase-2 expression. *J. Neurosci. Res.*, **58**, 593–598.
- SHOWELL, H.J., CONKLYN, M.J., ALPERT, R., HINGORANI, G.P., WRIGHT, K.F., SMITH, M.A., STAM, E., SALTER, E.D., SCAMPOLLI, D.N., MELTZER, S., REITER, L.A., KOCH, K., PISCOPIO, A.D., CORTINA, S.R., LOPEZ-ANAYA, A., PETTIPHER, E.R., MILICI, A.J. & GRIFFITHS, R.J. (1998). The preclinical pharmacological profile of the potent and selective leukotriene B₄ antagonist CP 195543. *J. Pharmacol. Exp. Ther.*, **285**, 946–954.
- SOUZA, D.G., CARA, D.C., CASSALI, G.D., COUTINHO, S.F., SILVEIRA, M.R., ANDRADE, S.P., POOLE, S.P. & TEIXEIRA, M.M. (2000a). Effects of the PAF receptor antagonist UK74505 on local and remote reperfusion injuries following ischaemia mesenteric artery in the rat. *Br. J. Pharmacol.*, **131**, 1800–1808.
- SOUZA, D.G., COUTINHO, S.F., SILVEIRA, M.R., CARA, D.C. & TEIXEIRA, M.M. (2000b). Effects of a BLT receptor antagonist on local and remote reperfusion injuries after transient ischemia of the superior mesenteric artery in rats. *Eur. J. Pharmacol.*, **403**, 121–128.
- STYLIANOOU, E. & SAKLATVALA, J. (1998). Interleukin-1. *Int. J. Biochem. Cell. Biol.*, **30**, 1075–1079.
- TEIXEIRA, M.M. & HELLEWELL, P.G. (1997). The effect of the selectin binding polysaccharide fucoidin on eosinophil recruitment *in vivo*. *Br. J. Pharmacol.*, **120**, 1059–1066.
- THORLACIUS, H., LINDBOM, L. & RAUD, J. (1997). Cytokine-induced leukocyte rolling in mouse cremaster muscle arterioles is P-selectin dependent. *Am. J. Physiol.*, **272**, H1725–H1729.
- VON ANDRIAN, U.H. & MACKAY, C.R. (2000). T-cell function and migration. Two sides of the same coin. *N. Engl. J. Med.*, **343**, 1020–1034.
- WANG, J.H. & SUN, G.Y. (2000). Platelet activating factor (PAF) antagonists on cytokine induction of iNOS and sPLA₂ in immortalized astrocytes. *Neurochem. Res.*, **25**, 613–619.
- WEN, F.Q., WATANABE, K. & YOSHIDA, M. (1998). Eicosanoid profile in culture human pulmonary artery smooth muscle cells treated with IL-1 β and TNF α . *Prostaglandins Leukot. Essent. Fatty Acids*, **59**, 71–75.
- WILLIAMS, F.M., KUS, M., TANDA, K. & WILLIAMS, T.J. (1994). Effect of duration of ischaemia on reduction of myocardial infarct size by inhibition of neutrophil accumulation using an anti-CD18 monoclonal antibody. *Br. J. Pharmacol.*, **111**, 1123–11987.
- ZIMMERMAN, M. (1983). Ethical guidelines for investigations of experimental pain in conscious animals. *Pain*, **16**, 109.

(Received August 1, 2001

Revised October 30, 2001

Accepted November 7, 2001)